Objective : The limitations of medical management of symptomatic intracranial arterial stenosis (ICS) have prompted development of new strategies, including endovascular treatment. However, stenting of symptomatic ICS remains investigational. Here, we have reported and analyzed a series of 19 endovascular procedures involving placement of a Wingspan stent.
INTRODUCTION
With widespread access to magnetic resonance imaging (MRI), computed tomographic angiography (CTA), and cerebral angiography, intracranial arterial stenosis (ICS) is increasingly diagnosed as a cause of cerebral ischemia. In the United States, 8 to 10% of ischemic strokes are attributed to ICS. 4 
Pre-procedural medication
To reduce the risk of periprocedural thrombosis and restenosis, aspirin (100 mg) or clopidogrel (75 mg) therapy was initiated in all patients at least five days before the procedure or patients were given 400 mg of aspirin and 300 mg of clopidogrel one day before 
Post-procedural management
All patients were admitted to an intensive care unit for approximately one day, and then transferred to the general ward until it was assured that there were no complications. After discharge, all patients were instructed to take 100 mg aspirin, 75 mg clopidogrel, and 10 mg atorvastatin daily for six months. Since the introduction of single lumen balloon microcatheters in 1992, PTA alone for intracranial stenosis has been used in some centers, and outcomes have compared favorably to those of medical treatment.
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In a study reported by Mark et al., 13) the 30-day rate for stroke and death was 5.8%, and the annual rate of stroke in the ipsilateral territory of the stenotic lesion was 3.2%. However, residual stenosis, periprocedural morbidity, and restenosis should also be considered;
in the same study, 40.7% of patients who were treated with PTA alone had residual stenosis of > 50%. To reduce the rate of residual stenosis, sufficient balloon inflation is needed, which can increase the risk of periprocedural morbidity, including dissection, arterial rupture, and distal embolization. Major periprocedural morbidity was reported in up to 50% of cases, with a fatality rate of 17%. 6) Among the morbidities, the incidence of vessel dissection was 20.2%, although, in some cases, this has been repaired with immediate stent implantation. 13) In addition, because PTA alone may have poor durability, the rate of restenosis is relatively high. In a nonrandomized single center database review, the rate of restenosis after PTA alone was 50%. 14) In treatment of coronary artery stenosis, PTAS showed better results than PTA alone. Because we did not perform follow-up MRIs, we reviewed other studies reporting on distal embolization seen on MRI. In a study of PTAS using the Wingspan stent, the incidence of distal embolization on diffusion MRI was 34.2%, and 70% in a study of PTAS using the balloon expandable stent. 
CONCLUSION
PTAS for symptomatic ICS can be safely and successfully performed using the Gateway balloon Wingspan stent system. Our initial experience suggests the potential for this procedure as a viable treatment option with a high rate of technical success and acceptable periprocedural morbidity for this patient population.
